These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 1978520)
1. Early dopamine agonist treatment in Parkinson's disease. Rinne UK Adv Neurol; 1990; 53():417-9. PubMed ID: 1978520 [No Abstract] [Full Text] [Related]
2. [Drug therapy of patients with early-stage parkinson's disease]. Kondo T Nihon Rinsho; 2000 Oct; 58(10):2055-60. PubMed ID: 11068446 [TBL] [Abstract][Full Text] [Related]
3. Early combination of dopamine agonist and levodopa in the treatment of Parkinson's disease. Rinne UK Mt Sinai J Med; 1988 Mar; 55(2):138-41. PubMed ID: 3260342 [No Abstract] [Full Text] [Related]
10. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Avanzi M; Uber E; Bonfà F Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629 [TBL] [Abstract][Full Text] [Related]
11. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]. Wedekind S MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622 [No Abstract] [Full Text] [Related]
12. [Current approaches in the treatment of Parkinson disease]. Caraceni T; Geminiani G; Tamma F Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471 [TBL] [Abstract][Full Text] [Related]
13. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study. Olanow CW; Werner EG; Gauger LL Clin Neuropharmacol; 1989 Dec; 12(6):490-7. PubMed ID: 2575014 [TBL] [Abstract][Full Text] [Related]
14. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease. Lieberman AN; Gopinathan G; Pasternack P; Goldstein M Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521 [No Abstract] [Full Text] [Related]
15. Early dopamine agonist therapy in Parkinson's disease. Rinne UK Mov Disord; 1989; 4 Suppl 1():S86-94. PubMed ID: 2566915 [No Abstract] [Full Text] [Related]
16. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087 [TBL] [Abstract][Full Text] [Related]
18. Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough. Montgomery EB Neurology; 2009 Jun; 72(24):2137; author reply 2137-8. PubMed ID: 19528526 [No Abstract] [Full Text] [Related]
19. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Olanow CW; Obeso JA Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513 [TBL] [Abstract][Full Text] [Related]